We are live on ! Find out more
XBI icon

State Street SPDR S&P Biotech ETF

659 hedge funds and large institutions have $9.04B invested in State Street SPDR S&P Biotech ETF in 2021 Q2 according to their latest regulatory filings, with 70 funds opening new positions, 249 increasing their positions, 180 reducing their positions, and 59 closing their positions.

New
Increased
Maintained
Reduced
Closed

38% more repeat investments, than reductions

Existing positions increased: 249 | Existing positions reduced: 180

19% more first-time investments, than exits

New positions opened: 70 | Existing positions closed: 59

3% more funds holding

Funds holding: 640 → 659 (+19)

15% less funds holding in top 10

Funds holding in top 10: 20 → 17 (-3)

29.88% less ownership

Funds ownership: 146.97% → 117.09% (-30%)

41% less call options, than puts

Call options by funds: $1.41B | Put options by funds: $2.37B

59% less capital inflows, than outflows

Capital inflows: $1.56B | Capital outflows: $3.82B

Holders
659
Holders Change
+19
Holders Change %
+2.97%
% of All Funds
11.43%
Holding in Top 10
17
Holding in Top 10 Change
-3
Holding in Top 10 Change %
-15%
% of All Funds
0.29%
New
70
Increased
249
Reduced
180
Closed
59
Calls
$1.41​B
Puts
$2.37​B
Net Calls
-⁠$965​M
Net Calls Change
+$612​M

XBI Hedge Fund Activity: Q2 2021 in Review

659 of the 5,768 institutional investors tracked by Wall St. Rank reported a position in State Street SPDR S&P Biotech ETF (XBI) for Q2 2021, worth a combined $9.04B — down 20% from $11.4B a quarter earlier.

Buyers outnumbered sellers: 70 funds opened new XBI positions and 59 closed out — a net gain of 11 holders — while 249 added to existing stakes and 180 trimmed.

The largest buyer was Toronto Dominion Bank, adding an estimated $838M. The largest seller was Morgan Stanley, cutting an estimated $1.23B.

  • 659 institutional investors held State Street SPDR S&P Biotech ETF (XBI) as of Q2 2021, up from 640 in Q1 2021.
  • Funds reported $9.04B of State Street SPDR S&P Biotech ETF stock for Q2 2021, down 20% quarter-over-quarter.
  • 70 funds opened new State Street SPDR S&P Biotech ETF positions in Q2 2021 and 59 closed out, a net change of +11 holders.
  • The largest State Street SPDR S&P Biotech ETF buyer in Q2 2021 was Toronto Dominion Bank, an estimated $838M added.
  • The largest State Street SPDR S&P Biotech ETF seller in Q2 2021 was Morgan Stanley, an estimated $1.23B sold.

Based on aggregated 13F filings for Q2 2021.